

requirements, EPA has determined that the additional SF for the protection of infants and children will be retained but reduced to 3x based on the following weight-of-the-evidence considerations relating to potential sensitivity and completeness of the data:

- There is concern for structure activity relationship. Imidacloprid, a chloronicotinyl compound, is an analog to nicotine and studies in the published literature suggest that nicotine, when administered causes developmental toxicity, including functional deficits, in animals and/or humans that are exposed *in utero*.

- There is evidence that imidacloprid administration causes neurotoxicity following a single oral dose in the acute study and alterations in brain weight in rats in the 2-year carcinogenicity study.

- The concern for structure activity relationship along with the evidence of neurotoxicity dictates the need of a developmental neurotoxicity study for assessment of potential alterations on functional development.

Because a developmental neurotoxicity study potentially relates to both acute and chronic effects in both the mother and the fetus, EPA has applied the additional UF for FQPA for all population subgroups, and in both acute and chronic risk assessments.

Based on the exposure assessments described above and on the completeness and reliability of the toxicity data, Bayer Corporation has concluded that the dietary exposure estimates from all label and pending uses of imidacloprid are 7.73% of the aPAD at the 99.9th percentile and 1.4% of the cPAD for the U.S. population. Thus, Bayer Corporation has concluded that there is a reasonable certainty that no harm will result from aggregate exposure to imidacloprid residues.

2. *Infants and children.* Based on the exposure assessments described above for the safety determination of the U.S. population and on the completeness and reliability of the toxicity data, Bayer Corporation has concluded that the dietary exposure estimates from all label and pending uses of imidacloprid are 16.42% of the aPAD at the 99.9th percentile and 3.0% of the cPAD for the most sensitive population subgroup, children 1 to 6 years. Thus, Bayer Corporation has concluded that there is a reasonable certainty that no harm will result from aggregate exposure to imidacloprid residues.

F. International Tolerances

No Codex maximum residue levels have been established for residues of

imidacloprid on any crops currently pending at EPA.

FR Doc. 03-2773 Filed 2-4-03; 8:45 a.m.]

BILLING CODE 6560-50-S

ENVIRONMENTAL PROTECTION AGENCY

[FRL-7448-3]

Jack Goins Waste Oil Superfund Site/ Cleveland, Tennessee; Notice of Proposed Settlement

AGENCY: Environmental Protection Agency.

ACTION: Notice of proposed settlement.

SUMMARY: Under section 122(h)(1) of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), the Environmental Protection Agency (EPA) has proposed to settle claims for response costs at the Jack Goins Waste Oil Superfund Site (Site) located in Cleveland, Tennessee, with Jack L. Goins, Susie T. Goins, Jack Goins Waste Oil Pumping Service, and Frances L. Lockmiller. EPA will consider public comments on the proposed settlement for thirty days. EPA may withdraw from or modify the proposed settlement should such comments disclose facts or considerations which indicate the proposed settlement is inappropriate, improper, or inadequate. Copies of the proposed settlement are available from: Ms. Paula V. Batchelor, U.S. Environmental Protection Agency, Region IV, Waste Management Division, 61 Forsyth Street, SW., Atlanta, Georgia 30303, (404) 562-8887.

Written comment may be submitted to Mr. Greg Armstrong at the above address within 30 days of the date of publication.

Dated: January 15, 2003.

Anita L. Davis,

Acting Chief, CERCLA Program Services Branch, Waste Management Division.

[FR Doc. 03-2769 Filed 2-4-03; 8:45 a.m.]

BILLING CODE 6560-50-P

FEDERAL MARITIME COMMISSION

Notice of Agreement(s) Filed

The Commission hereby gives notice of the filing of the following agreement(s) under the Shipping Act of 1984. Interested parties can review or obtain copies of agreements at the Washington, DC offices of the Commission, 800 North Capitol Street, NW., Room 940. Interested parties may submit comments on an agreement to

the Secretary, Federal Maritime Commission, Washington, DC 20573, within 10 days of the date this notice appears in the **Federal Register**.

Agreement No.: 011510-017.

Title: West African Discussion Agreement.

Parties: Atlantic Bulk Carriers, Ltd., HUAL AS, A.P. Moller Maersk Sealand, Mediterranean Shipping Company, P&O Nedlloyd Limited, Safmarine Container Lines NV, Zim Israel Navigation Company Ltd.

Synopsis: The amendment adds Safmarine Container Lines as a party to the agreement effective February 1, 2003.

Agreement No.: 011802-001.

Title: Evergreen/Lloyd Triestino/Hatsu Marine Alliance-WTSA Bridging Agreement.

Parties: The Evergreen/Lloyd Triestino/Hatsu Marine Alliance Agreement, Westbound Transpacific Stabilization Agreement.

Synopsis: The amendment updates the membership of the Westbound Transpacific Stabilization Agreement.

Agreement No.: 011839.

Title: Med-Gulf Space Charter Agreement.

Parties: Compania Chilena de Navegacion Interoceanica, Compania Sud-Americana de Vapores S.A., Lykes Lines Limited LLC.

Synopsis: The proposed agreement authorizes Lykes to charter space to the other parties in the trade between U.S. Gulf ports, including Miami, Florida, and San Juan, Puerto Rico, on the one hand, and ports in Spain, Italy, and Mexico, on the other hand.

Agreement No.: 201026-002.

Title: Port of New Orleans/P&O Ports Lease.

Parties: Port of New Orleans, P&O Ports Louisiana, Inc.

Synopsis: The modification expands the leased premises under the basic lease. The additional space may be used on an as-needed basis.

By Order of the Federal Maritime Commission.

Dated: January 31, 2003.

Bryant L. VanBrakle,
Secretary.

[FR Doc. 03-2791 Filed 2-4-03; 8:45 a.m.]

BILLING CODE 6730-01-P